Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04709718 |
| Other study ID # |
U23464 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 1, 2008 |
| Est. completion date |
January 2, 2020 |
Study information
| Verified date |
January 2021 |
| Source |
Université de Sousse |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Hepatic hemangiomas are the commonest benign mesenchymal lesions of the liver. Most of these
lesions are asymptomatic. Giant hepatic hemangiomas (GHH) (> 10 cm) are often symptomatic and
require surgical intervention. This study aimed to describe the clinical findings, risk
factors, diagnostic approach and management of GHH.
Description:
Hepatic hemangiomas are the most common benign tumors of the liver with the incidence of 0.4
to 20% . They are most often discovered incidentally on imaging studies. Typical hemangiomas
usually do not increase in size over time and therefore are unlikely to cause symptoms. Giant
hepatic hemangiomas (GHH) are defined as hemangiomas larger than 5 cm . They are usually
responsible for overt clinical symptoms and complications consisting, most often, of upper
abdominal pain, hemorrhage, biliary compression, or a consumptive coagulopathy that may
require prompt surgical intervention or other treatments . Management of liver hemangiomas
ranges from close observation to surgery depending upon the site, size and symptoms .
It is widely accepted that intervention is indicated only for symptomatic hemangiomas.
Surgical resection is indicated in patients with abdominal complaints or complications, or
when diagnosis remains inconclusive. The ideal surgical treatment for GHH is still
controversial. Enucleation is the preferred surgical method based on the existing literature.
In this study, we report our 17-year experience of clinical management of GHH.
